Introduction {#tca12568-sec-0005}
============

To date, chemotherapy is the primary treatment method for non‐small cell lung cancer (NSCLC). Although combination therapy of cisplatin with other medicine is the standard first‐line treatment for NSCLC, the efficacy of this regimen has reached a peak, with an efficacy rate of only 20%--35% and 10--12 months median survival.[1](#tca12568-bib-0001){ref-type="ref"} Individualized molecular target therapy according to NSCLC molecular phenotype has drawn attention in recent years. Statistical analysis has demonstrated that *EGFR* gene mutation in in Asian patients with advanced adenocarcinoma is as high as 51.4%.[2](#tca12568-bib-0002){ref-type="ref"} However, in the latest NSCLC cases, the number of patients with adenocarcinoma has dramatically increased to 60%.[3](#tca12568-bib-0003){ref-type="ref"} The development of EGFR‐tyrosine kinase inhibitors (TKI), applied as the first‐line treatment for NSCLC, has gradually shown advantages in efficacy and safety to treat sensitive mutant advanced NSCLC patients, especially patients with adenocarcinoma.

At present, *EGFR* mutation represents the optimal biomarker for predicting EGFR‐TKI sensitivity, suggesting that future therapy will be guided by *EGFR* sensitive mutations. In‐frame deletion of exon 19 (19Del) and missense mutation of exon 21(L858R) are the most common *EGFR* mutations in NSCLC, and have become the common biomarkers for predicting a clinical response to EGFR‐TKI. Nevertheless, there is no definitive conclusion regarding the differences in EGFR‐TKI efficacy for the treatment of both mutations. Further clinical data accumulation is necessary to explore the impact of EGFR‐TKI in NSCLC patients in order to clinically screen the optimal patients for EGFR‐TKI treatment.

In this study, advanced adenocarcinoma patients with 19Del and L858R were selected from the Jiangsu Province Hospital of Traditional Chinese Medicine between May 2014 and May 2017. All patients were defined without surgical indicators. The clinical efficacy of EGFR‐TKI treatment for both types of *EGFR* mutation was analyzed.

Methods {#tca12568-sec-0006}
=======

Clinical data {#tca12568-sec-0007}
-------------

A total of 145 adenocarcinoma patients diagnosed by pathology or cytology, at stages IIIb and IV according to 7th American Joint Committee on Cancer staging system, were tested using the amplification‐refractory mutation system to predict *EGFR* mutation. Adenocarcinoma staging was based on American Joint Committee on Cancer and Union for International Cancer Control tumor node metastasis (TNM) classifications. All testing specimens were taken from paraffin sections or fresh tumor tissues. Amplification‐refractory mutation system testing showed that 62 patients (men 22, women 40) had *EGFR* gene mutations, including 30 cases of 19Del mutation (48.8%), 28 cases of L858R mutation (45.2%) and 4 cases of G7I9X mutation. All mutations were single site mutations.

The selected 71 patients (mutation type 52, wild‐type 19) were treated with EGFR‐TKIs. Patient age ranged from 38 to 84 years, and there were 18 smokers and 53 non‐smokers. In the 52 mutation cases (men 19, women 33), there were 28 19Del and 24 L858R mutations, with 11 cases of stage IIIb and 41 of stage IV. In the 19 wild‐type patients (men 9, women 10), there were 3 cases of stage IIIb and 16 of stage IV. As computed tomography scanning revealed that 71 patients were ineligible for surgery, the efficacy estimation was conducted on these selected patients only.

Drug administration {#tca12568-sec-0008}
-------------------

Gefitinib (250 mg/d) or erlotinib (150 mg/d) were administered orally to patients until disease progression or death.

Indicators and treatment evaluations {#tca12568-sec-0009}
------------------------------------

Evaluation of the efficacy of EGFR‐TKIs commenced one month after the initiation of drug administration, and was then evaluated every two months. Timely re‐examination was conducted after disease progression. The final follow‐up visit occurred in April 2017. The median follow‐up duration was 15.8 months (range: 0.5\~30.1).

Immunological function testing: 4 ml of peripheral blood obtained from each patient was tested by flow cytometry to detect the number of T cell subsets before and after treatment to evaluate immune cell activity. X‐ray and computed tomography diagnosis results were compared before and after treatment.

Response rates (RRs), disease control rates (DCRs), progression‐free survival (PFS), and overall survival (OS) were analyzed in the 19Del, L858R, and wild‐type groups. Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were defined according to the Response Evaluation Criteria in Solid Tumors. PR and DCR were calculated using the following formulas: RR = (CR+PR)/total cases × 100% and DCR = (CR+PR+SD)/total cases × 100%. PFS was defined as the duration from initial drug administration to PD or death from any cause. If PD did not occur or the patient was still alive at the final follow‐up, the date of the last disease evaluation was recorded.

Statistical analysis {#tca12568-sec-0010}
--------------------

SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) was used to analyze the results. A chi‐square test was applied to analyze efficacy, while Kaplan--Meier curves and log‐rank tests were used to analyze survival. Multivariate analysis of factors influencing prognosis was performed by Cox proportional hazards model. *P* \< 0.05 was defined as statistically significant.

Results {#tca12568-sec-0011}
=======

Efficacy {#tca12568-sec-0012}
--------

Complete remission was not observed in either the mutation or wild‐type groups, while 40 cases of PR, 12 cases of SD, and 19 cases of PD were observed among the selected 71 patients. In the 19Del mutation group, the RR and DCR were 71.4% and 85.7%, respectively. In the L858R mutation group, the RR and DCR were 62.5% and 79.2%, respectively. The median PFS was 13 months (95% confidence interval \[CI\] 9.4--19.6) and the median OS was 30 months (95% CI 29.19--30.80) in the 19Del mutation group. In the L858R mutation group, the median PFS was 12 months (95% CI 9.8--14.2) and the median OS was 28 months (95% CI 22.5--33.5). The RR and DCR were higher and the PFS and OS were longer in the 19Del mutation group compared to the L858R mutation group. However, there was no statistically significant difference in RR, DCR, PFS, and OS between the two mutation groups (*P* = 0.494, 0.534, 0.55, and 0.21, respectively). The RR and DCR in both mutation groups was significantly higher than in the wild‐type *EGFR* group, while the PFS and OS in the mutation groups was dramatically prolonged compared to the wild‐type group, with statistical significance (Table [1](#tca12568-tbl-0001){ref-type="table-wrap"}).

###### 

Clinical efficacy of the three groups (*n* = 71)

              Recent curative effect (*n*, \[%\])               Long‐term effect (month, \[95%CI\])                                                                  
  ----------- ------------------------------------------------- ------------------------------------------------- -------------------------------------------------- ----------------------------------------------------
  19Del       20 (71.4)                                         24 (85.7)                                         13 (9--20)                                         30 (29--31)
  L858R       15 (62.5)                                         19 (79.2)                                         12 (10--14)                                        28 (22--34)
  Wild‐type   5 (26.3)[†](#tca12568-note-0001){ref-type="fn"}   9 (47.4)[†](#tca12568-note-0001){ref-type="fn"}   7 (6--11)[†](#tca12568-note-0001){ref-type="fn"}   15 (13--17)[†](#tca12568-note-0001){ref-type="fn"}

Compared to19Del and L858R groups (*P* \< 0.05). CI, confidence interval; DCR, disease control rate; OS, overall survival; PFS, progression‐free survival; RR, relative risk.

Impact factors of efficacy {#tca12568-sec-0013}
--------------------------

The χ^2^ test revealed that gender, smoking, and *EGFR* mutation were associated with short‐term treatment efficacy (*P* \< 0.05), while age, TNM staging classification, Eastern Cooperative Oncology Group performance status, and TKI drug selection were not impact factors (*P* \> 0.05). Log‐rank analysis determined that *EGFR* mutation type was correlated to PFS and OS (*P* \< 0.05), while gender, age, smoking, TNM staging classification, Eastern Cooperative Oncology Group performance status, and TKI drug selection were not associated with PFS or OS (*P* \> 0.05) (Table [2](#tca12568-tbl-0002){ref-type="table-wrap"}). Multivariate analysis indicated that disease control and *EGFR* mutation type were independent prognostic factors of OS (*P* \< 0.05) and that *EGFR* mutation status was closely associated with PFS (*P* = 0.05) (Table [3](#tca12568-tbl-0003){ref-type="table-wrap"}).

###### 

Efficacy analysis of 71 patients with advanced lung adenocarcinoma

  Characteristics   Case       mPFS      *P*            mOS      *P*       DCR (%)   *P*
  ----------------- ------ ------------- --------- ------------- --------- --------- ---------
  Gender                                 0.25                    0.24                0.01
  Male              28      11 (9--13)              25 (9--13)             57.1      
  Female            43      13 (10--14)             30 (26--30)            83.7      
  Age (year)                             0.64                    0.9                 0.68
  ≤ 65              42      13 (10--14)             27 (25--32)            71.4      
  \> 66             29      11 (10--15)             30 (20--30)            75.9      
  TNM stage                              0.28                    0.18                0.40
  IIIb              14      13 (8--18)              35 (15--38)            64.3      
  IV                57      11 (10--13)             28 (25--30)            75.4      
  Smoking                                0.88                    0.98                0.049
  Non‐smoker        18      12 (10--13)             29 (25--30)            79.3      
  Smoker            53      11 (7--16)              27 (15--36)            55.6      
  ECOG PS                                0.91                    0.1                 0.26
  0‐1               62      11 (10--13)             27 (25--30)            71.0      
  2                 9       12 (7--15)              33 (10--39)            88.9      
  TKI drug                               0.30                    0.24                0.90
  Gefitinib         37      11 (10--13)             26 (20--30)            72.9      
  Erlotinib         34      12 (10--15)             30 (25--35)            73.5      
  Mutation type                          \< 0.01                 \< 0.01             \< 0.01
  19del             28      13 (9--20)              30 (29--31)            85.7      
  L858R             24      12 (10--14)             28 (22--34)            79.2      
  Wild‐type         19       7 (6--11)              15 (13--17)            47.4      

All confidence intervals are 95%. DCR, disease control rate; ECOG PS, Eastern Cooperative Oncology Group performance status; mOS, median overall survival; mPFS, median progression‐free survival; TKI, tyrosine kinase inhibitor; TNM, tumor node metastasis.

###### 

Cox multivariate analysis of EGFRe xpression status with PFS and OS

              PFS     OS                                            
  ----------- ------- -------------- ------- ------- -------------- -------
  Gender      1.283   0.579--2.759   0.523   1.294   0.549--3.051   0.555
  Age         0.842   0.453--1.564   0.586   0.769   0.401--1.475   0.429
  Smoking     0.839   0.363--1.934   0.468   0.763   0.317--1.838   0.254
  TNM stage   1.485   0.563--3.916   0.424   1.781   0.660--4.802   0.546
  ECOG PS     0.917   0.586--1.435   0.704   0.592   0.341--1.027   0.062
  Efficacy    0.490   0.219--1.097   0.083   0.342   0.153--0.768   0.009
  EGFR type   0.610   0.368--1.012   0.055   0.207   0.096--0.446   0.000

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; TNM, tumor node metastasis.

Changes in T lymphocyte subsets and NK cell activity {#tca12568-sec-0014}
----------------------------------------------------

Following TKI treatment for 19Del and L858R mutations, CD3^+^, CD4^+^, and NK cell activity and the CD4^+^/CD8^+^ ratio increased in both groups; however, the results were not statistically significant (*P* \> 0.05). In the wild‐type group, CD3^+^, CD4^+^, and NK cell activity and the CD4^+^/CD8^+^ ratio decreased after TKI treatment; however, these results were also not statistically significant (*P* \> 0.05). Increases in T and NK cell activity in both the 19Del and L858R mutation groups were not statistically significant (*P* \> 0.05). Upregulation of immunological function was observed in both mutation groups, at 46.43% (13/28) in the 19Del mutation and 45.83% (11/24) in the L858R mutation group. Immune upregulation referred to increases in the number of CD4^+^ and NK cells observed. Although the differences between the two mutation groups were not statistically significant (χ^2^ = 0.3095; *P* = 0.578), the increase in both groups was significantly higher than in the wild‐type group at 15.79% (3/19) (19Del: χ^2^ = 6.838, *P* = 0.0089; L858R: χ^2^ = 4.359, *P* = 0.0368) (Table [4](#tca12568-tbl-0004){ref-type="table-wrap"}).

###### 

Changes in T lymphocyte subsets and NK cell activity in patients before and after therapy

                                        (\[X̄ ± S\] %)                
  --------------- --------------------- --------------- ------------ ------------
  CD3^+^          Before chemotherapy   73.60±1.33      70.41±1.09   73.89±1.08
                  After chemotherapy    74.17±1.27      72.44±1.04   72.52±1.30
  CD4^+^          Before chemotherapy   31.83±1.70      31.05±1.64   30.18±1.99
                  After chemotherapy    34.23±1.96      31.95±1.71   27.39±1.72
  CD4^+^/CD8^+^   Before chemotherapy   1.00±0.12       1.02±0.12    0.88±0.12
                  After chemotherapy    1.14±0.12       1.04±0.98    0.69±0.07
  NK cell         Before chemotherapy   16.39±1.28      15.56±1.26   14.58±1.35
                  After chemotherapy    16.90±1.09      16.00±1.18   13.85±1.13

Discussion {#tca12568-sec-0015}
==========

Exploration of *EGFR* mutations and evaluation of the efficacy and safety of molecular target drugs in clinical use has proven that EGFR‐TKIs have significant efficacy and safety for treating *EGFR*‐sensitive advanced adenocarcinoma. EGFR‐TKI treatment has demonstrated great benefit to patients with lung cancer and has increased the survival rate. The IPASS study was the first to demonstrate a significant correlation between *EGFR*‐sensitive mutations and gefitinib treatment efficacy.[4](#tca12568-bib-0004){ref-type="ref"}Following the IPASS study, clinical results of phase III trials OPTIMAL, NEJ002, EURTAC, and WJT03405 showed that EGFR‐TKI as first‐line therapy could greatly improve quality of life and prolong PFS in lung cancer patients with *EGFR* mutations compared to chemotherapy.

The most common *EGFR* mutations detected in our study were19Del (45%) and L858R (40--45%). These two mutations account for 85\~90% of *EGFR* mutations.[5](#tca12568-bib-0005){ref-type="ref"} Previous studies have reported that an EGFR‐TKI probe was more effective for treating patients with 19Del mutations than patients with L858R mutations, with more significant clinical outcomes and favorable median PFS and OS rates in the 19Del mutation group.[6](#tca12568-bib-0006){ref-type="ref"}, [7](#tca12568-bib-0007){ref-type="ref"}, [8](#tca12568-bib-0008){ref-type="ref"}, [9](#tca12568-bib-0009){ref-type="ref"} However, inconsistent outcomes have also been reported in some phase III clinical trials. These phase III trial results suggested that there was no significant difference in PFS in patients with19Del and L858R mutations treated with TKIs.[10](#tca12568-bib-0010){ref-type="ref"}This result requires confirmation by more evidence‐based and basic research.

This retrospective analysis of patients with *EGFR* mutations treated with EGFR‐TKIs yielded RRs of 71.4% and 62.5%, and DCRs of 85.7% and 79.2% in the 19Del and L858R groups, respectively. In the 19Del group, the median PFS and median OS rates were 13 months (95% CI 9.4--19.6) and 30 months (95% CI 29.19--30.80), respectively. In the L858R group, the median PFS and OS was 12 months (95% CI = 9.8--14.2) and 28 months (95% CI = 22.5--33.5), respectively. Significant favorable ORR, DCR, PFS, and OS were observed int he mutation groups compared to the wild‐type group (*P* \< 0.05). These results showed that TKIs could be effectively used to treat *EGFR*‐sensitive mutated disease. Further comparison between the two mutation groups revealed higher RR and DCR in the 19Del group compared to the L858R group. In addition, longer median PFS and OS rates were observed in the 19Del group. Although there were no statistically significant differences in RR, DCR, PFS, and OS between the mutation groups (*P* = 0.494, 0.534, 0.55, and 0.21, respectively), the results indicated that EGFR‐TKI treatment was more effective in patients with 19Del mutations. The small size of the patient sample may explain why no statistically significant differences were observed between the two mutation groups.

Further correlation analysis regarding clinical characteristics and efficacy implied that gender and smoking were associated with DCR. A short‐term TKI treatment advantage was observed in non‐smoking female patients. The association between DCR, PFS, OS, and *EGFR* mutation type suggested the clinical efficacy of using TKIs to treat *EGFR*‐sensitive mutations. The data showed that the use of different kinds of TKI drugs had no significant impact on DCR, PFS, or OS, indicating that the selection of TKI drugs has no dramatic influence on prognosis after treatment.

The results of Cox analysis suggested that the disease control profile and *EGFR* mutation status (*P* \< 0.05) were independent prognostic factors of OS. *EGFR* mutation status was closely associated with PFS (*P* = 0.055), consistent with the results of previous studies.[11](#tca12568-bib-0011){ref-type="ref"}, [12](#tca12568-bib-0012){ref-type="ref"} However, this result requires confirmation by studies using larger samples.

Downregulation and immune system dysfunction, along with the hypofunction of T and NK cells, was observed in advanced lung cancer patients during tumor progression. Cellular immune function is suppressed in cancer patients and as such, cannot activate an immune response. However, the survival duration in lung cancer patients was prolonged after immunotherapy with mixed T and NK effector cells.[13](#tca12568-bib-0013){ref-type="ref"} Studies have indicated that TKI drugs stimulate important immunoregulatory activity by participating in the development and activation of immune cells, leading to the activation of T and NK cells. Therefore, elevating the sensitivity of tumor cells to immune regulation enhances the immunologic function of immune cells. It is accepted that the CD4^+^/CD8^+^ratio and NK cells may be helpful prognostic indicators for TKI treatment efficacy in advanced NSCLC patients.[14](#tca12568-bib-0014){ref-type="ref"}, [15](#tca12568-bib-0015){ref-type="ref"}Dasatinib has been reported to promote the proliferation of T and NK cells, which could reverse the abnormal immune state of cancer patients to a favorable state.[16](#tca12568-bib-0016){ref-type="ref"}

The results of the present study indicated that CD3^+^, CD4^+^, and NK cell activity and the CD4^+^/CD8^+^ratio was improved after TKI treatment in both 19Del and L858R mutation groups; however, these results were not statistically significant (*P* \> 0.05). Decreased activity of CD3^+^, CD4^+^, and NK cells and the CD4^+^/CD8^+^ ratio was observed in the wild‐type group after TKI treatment; however, these results were also not statistically significant (*P* \> 0.05). There was no statistically significant difference in increases in the degree of viability of these immune cells before and after TKI treatment in either mutation group (*P* \> 0.05). After TKI treatment, upregulation of immunologic function was observed in 46.43% of 19Del and 45.83% of L858R mutation patients (χ^2^ = 0.3095; *P* = 0.578). Although there was no statistically significant difference, the number of patients with immunological upregulation in both mutation groups was higher compared to the wild‐type group. These results indicate that TKI treatment was effective for improving immunological function in advanced lung cancer patients with *EGFR* mutations.

In conclusion, *EGFR* mutation is the main impact factor of the clinical efficacy of TKI treatment for advanced adenocarcinoma. Compared to the L858R mutation group, higher RR and DCR and longer median PFS and OS rates were observed in the 19Del mutation group, demonstrating that TKI treatment was more effective for patients with 19Del mutations. As no statistically significant differences between the mutation groups were observed, further prospective randomized controlled studies of TKI treatment efficacy for patients with *EGFR* mutations should be conducted with large patient samples. Moreover, mechanisms behind the biological behavior of different *EGFR* mutant subtypes should also be explored.
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